{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:35:58Z","timestamp":1774967758709,"version":"3.50.1"},"reference-count":44,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n                    <jats:p>Optimal treatment decisions in children require sufficient evidence on the safety and efficacy of pharmaceuticals in pediatric patients. However, there is concern that not enough trials are conducted in children and that pediatric trials differ from those performed in adults. Our objective was to measure the prevalence of pediatric studies among clinical drug trials and compare trial characteristics and quality indicators between pediatric and adult drug trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>For conditions representing a high burden of pediatric disease, we identified all drug trials registered in ClinicalTrials.gov with start dates between 2006 and 2011 and tracked the resulting publications. We measured the proportion of pediatric trials and subjects for each condition and compared pediatric and adult trial characteristics and quality indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>For the conditions selected, 59.9% of the disease burden was attributable to children, but only 12.0% (292\/2440) of trials were pediatric (P &amp;lt; .001). Among pediatric trials, 58.6% were conducted without industry funding compared with 35.0% of adult trials (P &amp;lt; .001).<\/jats:p>\n                    <jats:p>Fewer pediatric compared with adult randomized trials examined safety outcomes (10.1% vs 16.9%, P = .008). Pediatric randomized trials were slightly more likely to be appropriately registered before study start (46.9% vs 39.3%, P = .04) and had a modestly higher probability of publication in the examined time frame (32.8% vs 23.2%, P = .04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>There is substantial discrepancy between pediatric burden of disease and the amount of clinical trial research devoted to pediatric populations. This may be related in part to trial funding, with pediatric trials relying primarily on government and nonprofit organizations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2012-0139","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T20:35:16Z","timestamp":1343075716000},"page":"285-292","source":"Crossref","is-referenced-by-count":125,"title":["Pediatric Versus Adult Drug Trials for Conditions With High Pediatric Disease Burden"],"prefix":"10.1542","volume":"130","author":[{"given":"Florence T.","family":"Bourgeois","sequence":"first","affiliation":[{"name":"Division of Emergency Medicine and"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts;"}]},{"given":"Srinivas","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital for Sick Children, Toronto, Canada;"}]},{"given":"Catia","family":"Pinto","sequence":"additional","affiliation":[{"name":"Public Health Unit, North Lisbon Healthcare Centers, Lisbon, Portugal; and"}]},{"given":"Karen L.","family":"Olson","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine and"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts;"},{"name":"Children\u2019s Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Children\u2019s Hospital Boston, Boston, Massachusetts;"}]},{"given":"John P.A.","family":"Ioannidis","sequence":"additional","affiliation":[{"name":"Stanford Prevention Research Center, Department of Medicine, and"},{"name":"Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California"}]},{"given":"Kenneth D.","family":"Mandl","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine and"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts;"},{"name":"Children\u2019s Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Children\u2019s Hospital Boston, Boston, Massachusetts;"}]}],"member":"417","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"issue":"9","key":"2021120821034872000_B1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00431-005-1698-8","article-title":"A literature review on off-label drug use in children.","volume":"164","author":"Pandolfini","year":"2005","journal-title":"Eur J Pediatr"},{"issue":"3","key":"2021120821034872000_B2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archpedi.161.3.282","article-title":"Off-label drug use in hospitalized children.","volume":"161","author":"Shah","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"9436","key":"2021120821034872000_B3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(04)16942-0","article-title":"Clinical trials in children.","volume":"364","author":"Caldwell","year":"2004","journal-title":"Lancet"},{"key":"2021120821034872000_B4","doi-asserted-by":"crossref","first-page":"SII21","DOI":"10.1016\/S0140-6736(99)90253-2","article-title":"Research in children: ethical and scientific aspects.","volume":"354","author":"Smyth","year":"1999","journal-title":"Lancet"},{"issue":"18","key":"2021120821034872000_B5","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJMhpr021646","article-title":"Testing medications in children.","volume":"347","author":"Steinbrook","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"2021120821034872000_B6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-2125.2010.03881.x","article-title":"Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.","volume":"71","author":"Lindkvist","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2021120821034872000_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.2007.02987.x","article-title":"Off-label and unlicensed prescribing for children: have we made any progress?","volume":"64","author":"Waller","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2021120821034872000_B8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2021120821034872000_B9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/clinids\/3.3.479","article-title":"Chloramphenicol: a review of its use in clinical practice.","volume":"3","author":"Feder","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"9159","key":"2021120821034872000_B10","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(99)90018-1","article-title":"Propofol-infusion syndrome in children.","volume":"353","author":"Hatch","year":"1999","journal-title":"Lancet"},{"key":"2021120821034872000_B11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2431-10-96","article-title":"A descriptive analysis of a representative sample of pediatric randomized controlled trials published in 2007.","volume":"10","author":"Hamm","year":"2010","journal-title":"BMC Pediatr"},{"issue":"3","key":"2021120821034872000_B12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archpediatrics.2009.291","article-title":"Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985-2005.","volume":"164","author":"Cohen","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"2021120821034872000_B13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1542\/peds.2007-2849","article-title":"Child versus adult research: the gap in high-quality study design.","volume":"122","author":"Martinez-Castaldi","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"2021120821034872000_B14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jclinepi.2006.03.015","article-title":"An absence of pediatric randomized controlled trials in general medical journals, 1985-2004.","volume":"60","author":"Cohen","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"2021120821034872000_B15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/adc.2009.165902","article-title":"A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period.","volume":"95","author":"Anderson","year":"2010","journal-title":"Arch Dis Child"},{"issue":"6","key":"2021120821034872000_B16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/adc.2009.173591","article-title":"A systematic review of paediatric randomised controlled drug trials published in 2007.","volume":"95","author":"Aripin","year":"2010","journal-title":"Arch Dis Child"},{"issue":"2","key":"2021120821034872000_B17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11316260-000000000-00000","article-title":"Published pediatric randomized drug trials in developing countries, 1996-2002.","volume":"12","author":"Nor Aripin","year":"2010","journal-title":"Paediatr Drugs"},{"key":"2021120821034872000_B18","unstructured":"World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: World Health Organization; 2008. Available at: www.who.int\/evidence\/bod. Accessed May 5, 2012"},{"issue":"24","key":"2021120821034872000_B19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJM199906173402406","article-title":"The relation between funding by the National Institutes of Health and the burden of disease.","volume":"340","author":"Gross","year":"1999","journal-title":"N Engl J Med"},{"issue":"7339","key":"2021120821034872000_B20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.324.7339.702","article-title":"Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research.","volume":"324","author":"Isaakidis","year":"2002","journal-title":"BMJ"},{"key":"2021120821034872000_B21","unstructured":"National Institutes of Health. ClinicalTrials.gov. Available at: www.clinicaltrials.gov. Accessed May 5, 2012"},{"issue":"3","key":"2021120821034872000_B22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/archinternmed.2011.1209","article-title":"Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis.","volume":"172","author":"Estellat","year":"2012","journal-title":"Arch Intern Med"},{"issue":"2","key":"2021120821034872000_B23","doi-asserted-by":"crossref","first-page":"e14701","DOI":"10.1371\/journal.pone.0014701","article-title":"The quality of registration of clinical trials.","volume":"6","author":"Viergever","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"2021120821034872000_B24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/0003-4819-153-3-201008030-00006","article-title":"Outcome reporting among drug trials registered in ClinicalTrials.gov.","volume":"153","author":"Bourgeois","year":"2010","journal-title":"Ann Intern Med"},{"issue":"9","key":"2021120821034872000_B25","doi-asserted-by":"crossref","first-page":"e13106","DOI":"10.1371\/journal.pone.0013106","article-title":"Controlled trials in children: quantity, methodological quality and descriptive characteristics of pediatric controlled trials published 1948-2006.","volume":"5","author":"Thomson","year":"2010","journal-title":"PLoS ONE"},{"key":"2021120821034872000_B26","unstructured":"Institute of Medicine. Learning what works best: the nation's need for evidence on comparative effectiveness in health care. 2007. Available at: www.iom.edu\/\u223c\/media\/Files\/Activity%20Files\/Quality\/VSRT\/ComparativeEffectivenessWhitePaperF.ashx. Accessed May 5, 2012"},{"issue":"9","key":"2021120821034872000_B27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database\u2014update and key issues.","volume":"364","author":"Zarin","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"2021120821034872000_B28","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1371\/journal.pmed.0050191","article-title":"Publication of clinical trials supporting successful new drug applications: a literature analysis.","volume":"5","author":"Lee","year":"2008","journal-title":"PLoS Med"},{"issue":"4","key":"2021120821034872000_B29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.279.4.281","article-title":"Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials.","volume":"279","author":"Ioannidis","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"2021120821034872000_B30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1542\/peds.98.1.118","article-title":"Is the \u201ctherapeutic orphan\u201d about to be adopted?","volume":"98","author":"Cot\u00e9","year":"1996","journal-title":"Pediatrics"},{"issue":"7","key":"2021120821034872000_B31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jama.290.7.905","article-title":"Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.","volume":"290","author":"Roberts","year":"2003","journal-title":"JAMA"},{"key":"2021120821034872000_B32"},{"key":"2021120821034872000_B33","year":"2007"},{"key":"2021120821034872000_B34"},{"issue":"7632","key":"2021120821034872000_B35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/bmj.39400.376424.BE","article-title":"Regulation of drugs for children in Europe.","volume":"335","author":"Choonara","year":"2007","journal-title":"BMJ"},{"issue":"7632","key":"2021120821034872000_B36","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39423.581042.DB","article-title":"WHO launches campaign to make drugs safer for children.","volume":"335","author":"Watts","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"2021120821034872000_B37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.annemergmed.2008.06.009","article-title":"Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research.","volume":"52","author":"Berger","year":"2008","journal-title":"Ann Emerg Med"},{"issue":"4","key":"2021120821034872000_B38","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.","volume":"170","author":"Bhandari","year":"2004","journal-title":"CMAJ"},{"issue":"2","key":"2021120821034872000_B39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00228-005-0894-9","article-title":"Clinical trials of medication in children, 1996-2002.","volume":"61","author":"Sammons","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"9173","key":"2021120821034872000_B40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(05)75299-5","article-title":"Drug development output: what proportion for tropical diseases?","volume":"354","author":"Trouiller","year":"1999","journal-title":"Lancet"},{"issue":"9116","key":"2021120821034872000_B41","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0140-6736(97)10237-9","article-title":"Health research in the tropics.","volume":"351","author":"Wolffers","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"2021120821034872000_B42","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1371\/journal.pmed.0050230","article-title":"Bias, spin, and misreporting: time for full access to trial protocols and results.","volume":"5","author":"Chan","year":"2008","journal-title":"PLoS Med"},{"issue":"9346","key":"2021120821034872000_B43","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0140-6736(02)11652-7","article-title":"The power of the protocol.","volume":"360","author":"Lassere","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"2021120821034872000_B44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jpeds.2010.02.011","article-title":"Comparative effectiveness of medical interventions in adults versus children.","volume":"157","author":"Contopoulos-Ioannidis","year":"2010","journal-title":"J Pediatr."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/130\/2\/285\/1088157\/peds_2012-0139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/130\/2\/285\/1088157\/peds_2012-0139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T19:59:32Z","timestamp":1638993572000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/130\/2\/285\/29887\/Pediatric-Versus-Adult-Drug-Trials-for-Conditions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,8,1]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2012-0139","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717964956.793466103","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}